Volume 6.09 | Mar 13

Mammary Cell News 6.09 March 13, 2014
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  ESC & iPSC News on Twitter
 
TOP STORY
SERMs Attenuate Estrogen-Induced Malignant Transformation of Human Breast Epithelial Cells by Upregulating Detoxification of Oxidative Metabolites
Non-tumorigenic MCF-10A human breast epithelial cells are classified as estrogen receptor(-) and undergo estrogen-induced malignant transformation. Selective estrogen receptor modulators (SERMs), in use for breast cancer chemoprevention and for post-menopausal osteoporosis, were observed to inhibit malignant transformation, as measured by anchorage-independent colony growth. [Cancer Prev Res] Abstract
Alt Text - Protocol and Data: Serum-Free, 3D Suspension Assay for Breast Cancer Cells
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

PPAR? and RXR Ligands Disrupt the Inflammatory Cross-Talk in the Hypoxic Breast Cancer Stem Cells Niche
Researchers found that 6-OH-11-O-hydroxyphenanthrene potentiates the ability of pioglitazone to hamper the mammospheres-forming capability of human breast tumors and MCF7 cancer cells, reducing the expression of cancer stem cells regulatory genes. [J Cell Physiol] Abstract

The Apoptotic Effect of D Rhamnose ß-Hederin, a Novel Oleanane-Type Triterpenoid Saponin on Breast Cancer Cells
D Rhamnose ß-hederin showed strong inhibitory activity on the growth of various breast cancer cells and induced apoptosis in these cells. [PLoS One] Full Article

Vasoinhibins, N-Terminal Mouse Prolactin Fragments, Participate in Mammary Gland Involution
Incubation of mammary gland fragments and MCF7 with 16kDa mouse prolactin recombinant provided a proapoptotic effect in mammary epithelial cells. [J Mol Endocrinol] Abstract

The Inflammatory Cytokine TNFalpha Cooperates with Ras in Elevating Metastasis and Turns WT-Ras to a Tumor-Promoting Entity in MCF-7 Cells
TNFalpha cooperates with Ras in promoting the metastatic phenotype of MCF-7 breast tumor cells, and turns WT-Ras into a tumor-supporting entity. [BMC Cancer] Abstract | Full Article

Mechanisms Underlying Differential Response to Estrogen-Induced Apoptosis in Long-Term Estrogen-Deprived Breast Cancer Cells
Data suggests that MCF-7:2A cells employ stronger antioxidant defense mechanisms than do MCF-7:5C cells, and that oxidative stress is ultimately required for MCF-7:2A cells to die in response to estradiol treatment. [Int J Oncol] Abstract

Bone-Derived Soluble Factors and Laminin-511 Cooperate to Promote Migration, Invasion and Survival of Bone-Metastatic Breast Tumor Cells
Scientists used the bone-metastatic 4T1BM2 mammary carcinoma model to investigate the cooperative interactions between tumor LM-511 and bone-derived soluble factors in vitro. [Growth Factors] Abstract

Silencing of ETS1 Reverses Adriamycin Resistance in MCF-7/ADR Cells via Downregulation of MDR1
Researchers investigated the effects of Erythroblastosis virus E26 oncogene homolog 1 (ETS1) on adriamycin resistance in MCF-7/ADR cells. ETS1 mRNA and protein was significantly overexpressed in MCF-7/ADR cells, compared to MCF-7 cells. [Cancer Cell Int] Abstract | Full Article

Normal Mammary Development and Function in Mice with Ift88 Deleted in MMTV- and K14-Cre Expressing Cells
Researchers developed mouse models with deletion of primary cilia (PC) in mammary luminal epithelial, basal epithelial, and stromal cells for evaluation of the function of PC in mammary development via MMTV-Cre, K14-Cre, and Prx1-Cre mediated deletion, respectively. [Cilia] Full Article

CLINICAL RESEARCH

Multicenter Phase II Study of Apatinib, a Novel VEGFR Inhibitor in Heavily Pretreated Patients with Metastatic Triple Negative Breast Cancer
Investigators evaluated the optimum dose level for the efficacy and safety of apatinib monotherapy in heavily pretreated patients with metastatic triple negative breast cancer in China. [Int J Cancer] Abstract

Temsirolimus and Pegylated Liposomal Doxorubicin (PLD) Combination Therapy in Breast, Endometrial, and Ovarian Cancer: Phase Ib Results and Prediction of Clinical Outcome with FDG-PET/CT
Preclinical data suggest that the combination of PLD with a mammalian target of rapamycin inhibitor has an additive effect. The safety and recommended phase two dose of temsirolimus in combination with PLD were assessed. [Target Oncol] Abstract

Robust Growth of Human Mammary Luminal & Myoepithelial Cells with Serum-Free EpiCult-C (Human) Request a Free Sample
 
REVIEWS
The Emergence of Targeted Drugs in Breast Cancer to Prevent Resistance to Endocrine Treatment and Chemotherapy
The authors provide an overview of novel targeted agents currently explored in clinical breast cancer trials and registered in ClinicalTrials.gov. The main focus will be on their ability to prevent or reverse endocrine resistance and chemoresistance in breast cancer. [Expert Opin Pharmacother] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
 
INDUSTRY NEWS
Synta and QuantumLeap Healthcare Collaborative Announce Selection of Ganetespib for I-SPY 2 TRIAL in Breast Cancer
Synta Pharmaceuticals Corp. and QuantumLeap Healthcare Collaborative announced that Synta’s lead drug candidate, the Hsp90 inhibitor ganetespib, has been selected for study in the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2). [Synta Pharmaceuticals Corp.] Press Release

Rexahn Announces Initial Results from Phase I Trial of Supinoxin™ (RX-5902) for Solid Cancer Tumors
Rexahn Pharmaceuticals, Inc. announced initial data for the Phase I dose-escalation clinical trial of Supinoxin™ initiated in August 2013. In preclinical studies, Supinoxin has been shown to inhibit proliferation of cancer cells in 18 human cancer cell lines including breast, colon, pancreas, ovarian, and stomach cancers, and showed potent activity in drug-resistant cancer cells. [Rexahn Pharmaceuticals, Inc.] Press Release

Tennessee Oncology Is First in Tennessee to Use Test to Determine Risk of Both Early and Late Breast Cancer Recurrence and Likelihood of Benefit from Extended Endocrine Therapy
Tennessee Oncology has announced its adoption of the breakthrough, Breast Cancer IndexSM, from bioTheranostics, Inc. This new test allows patients and their oncologists to more effectively manage their individual cancer treatment. [Tennessee Oncology] Press Release

From our sponsor:
Looking for ALDH+ cancer stem cells? Watch a video to see how ALDEFLUORTM can help.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW World Stem Cells & Regenerative Medicine Congress 2014
May 20-22, 2014
London, United Kingdom

Visit our events page to see a complete list of events in the mammary cell community.
 
JOB OPPORTUNITIES
NEW Research Assistant – Breast Epithelial Cell Research (Mount Sinai Medical Center/Icahn School of Medicine at Mount Sinai)

Director of GMP/GLP Quality Operations (University of Pennsylvania, Perelman School of Medicine)

Postdoctoral Positions – Breast Cancer (Karolinska Institute)

Postdoctoral Fellow – Process of Mammary Differentiation (University of British Columbia)

Postdoctoral Fellow – Mechanisms that Contribute to Metastases of Breast Cancer Cells (Mount Sinai Medical Center/Icahn School of Medicine at Mount Sinai)

Postdoctoral Fellow – Hodgkin Lymphoma and Breast Cancer (Hackensack University Medical Center)

Postdoctoral Position – Functions of Epigenetic Enzymes in Breast Cancer (University of Wisconsin-Madison)

Postdoctoral Position – Breast Cancer Metastasis (Weizmann Institute of Science)

Postdoctoral Research Fellow (Brigham & Women’s Hospital and Harvard Medical School)

Scientific Communications & Publishing Coordinator (STEMCELL Technologies, Inc.)

Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Submit your feedback here.
Learn more about Mammary Cell News: Archives | Events | Contact Us